An LFS pedigree showing for the first time familial clustering of AML. The index patient developed tAML (II:4) following cytotoxic treatment of diverse antecedent malignancies, and the index patient’s father (I:2) developed sAML following myelodysplasia. Filled symbols, subjects with malignancies; asterisk denotes a TP53 c.467G>C, p.R156P germ line mutation carrier; the “minus” denotes a wild-type TP53 germ line status. Numbers in brackets indicate age at diagnosis in years. BC, breast cancer; CML, chronic myeloid leukemia; CRC, colorectal cancer; PNET, primitive neuroectodermal tumor; TC, thyroid carcinoma.